Ophthalmologica
Case Report · Description de cas · Fallbericht
Cataract Induced by Short-Term Administration of Large Doses of Busulfan: A Case ReportKaida T. · Ogawa T. · Amemiya T.Department of Ophthalmology, Nagasaki University, School of Medicine, Nagasaki, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: November 02, 1999
Issue release date: November – December
Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Abstract
Busulfan is a carcinostatic which is used for myelocytic leukemia. A 42-year-old Japanese woman given high doses of busulfan for a short time was referred to us because of decreased visual acuity and blurred vision in both eyes. She received 212 mg/day of busulfan for only 4 days. Ophthalmoscopic examination demonstrated a posterior polar subcapsular opacity of the lens in both eyes. Although the occurrence of cataract due to busulfan has been reported after long-term administration of busulfan, this is the first clinical case of cataract caused by high doses of busulfan for a short period. It is necessary to pay more attention to busulfan cataract.
© 1999 S. Karger AG, Basel
Related Articles:
References
-
Grimes P, von Sallmann L, Frichette A: Influence of Myleran on cell proliferation in the lens epithelium. Invest Ophthalmol 1964;3:566–576.
- Oldrich S, Medvedovski C, Merriam GR, Worgul BV: Micronucleation in the lens epithelium following in vivo exposure to physical and chemical mutagens. Lens Res 1988;5:203–216.
- Ganly PS, Arthur C, Goldman JM, Schulenburg WE: Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Postgrad Med J 1988;64:389–391.
- Akman N, Avanoglu Y, Soysal T: Cataract after busulfan therapy. Acta Haematol 1986;76:236.
-
Ravindranathan MP, Paul VJ, Kuriakose E: Cataract after busulfan treatment. Br Med J 1972;i:218–219.
- Japp H: Toxische Effekte von Busulfan (Myleran) bei der Behandlung der chronischen myelischen Leukämie. Schweiz Med Wochenschr 1974;104:1115–1119.
-
Podos S, Canellos G: Ocular toxicity of busulfan. Am J Ophthalmol 1959;68:500–504.
-
Honda A, Dake Y, Amemiya T: Cataracts in a patient treated with busulfan (Mablin powder) for eight years. J Jpn Ophthalmol Soc 1993;97:1242–1245.
-
Eida H, Dake Y, Amemiya T: A case of cataract following long term systemic busulfan therapy. Rinsho Ganka (J Clin Ophthalmol) 1995;49:1761–1764.
-
Colvin M: Cancer Chemotherapy. Philadelphia, Lippincott, 1990, pp 276–313.
-
Taniguchi T, Takimoto T, Yamamura T: Long-term follow-up study of steroid cataracts in renal transplant patients – Recent situation before and after induction of ciclosporin. Atarashii Ganka (J Eye) 1988;5:1619–1622.
- Frandsen E: Spontaneous absorption of cortisone-induced cataracts. Acta Ophthalmol 1965;43:605–609.
Article / Publication Details
Published online: November 02, 1999
Issue release date: November – December
Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
